Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
BMC Cancer|July 7, 2022
CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I studyTomoyuki Otsuka, Sumiyuki Nishida, Takayuki Shibahara, et al.
Cancer Chemotherapy and Pharmacology|July 9, 2017
Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 studyTakayuki Shiroyama, Motohiro Tamiya, Seigo Minami, et al.
Clinical Case Reports|February 28, 2022
COVID-19 in a human T-cell lymphotropic virus type-1 carrierTakatoshi Enomoto, Takayuki Shiroyama, Haruhiko Hirata, et al.
Scientific Reports|October 19, 2022
Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patientsKota Iwahori, Takeshi Uenami, Yukihiro Yano, et al.
Respiratory Medicine|September 11, 2025
Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosisTakayuki Niitsu, Kiyoharu Fukushima, Sho Komukai, et al.
Investigational New Drugs|November 22, 2025
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in JapanYasuhiro Mihashi, Kiyohide Komuta, Akihiro Tsukaguchi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2025
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter studyAkihiro Tsukaguchi, Kinnosuke Matsumoto, Akihiro Tamiya, et al.
Cancer Research Communications|January 5, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer CohortMakoto Nishio, Shuji Murakami, Hisato Kawakami, et al.
RMD Open|January 23, 2023
Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung diseaseTakayuki Niitsu, Kiyoharu Fukushima, Sho Komukai, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort studyYuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Pageof 14